Fazal Raziq, MD
Pulmonary Disease · Green Bay, WINPI 1265928915
Payments from drug & device makers
What this record shows
This record is dominated by education: $5,517 of the $7,536 with a category attached, or 73.2%. Intuitive Surgical accounts for 90.3% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $6,266, more than ten times the $104 reported in 2019.
Across 29 payments — averaging $259.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Sanofi$146
- Boehringer Ingelheim$105
- Merck$92
- Johnson & Johnson$83
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$81
- plus $220 from 8 others
What the payments were for
- Travel & lodging$1,29517%
- Food & beverage$72410%
- Education$5,51773%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $6,808 |
| Sanofi | 2 | $146 |
| Boehringer Ingelheim | 1 | $105 |
| Merck | 1 | $92 |
| Johnson & Johnson | 1 | $83 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $81 |
| Regeneron Healthcare Solutions, Inc. | 1 | $46 |
| Boston Scientific | 2 | $44 |
| Insmed, Inc. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Novartis | 1 | $20 |
| Gilead | 1 | $19 |
| Genentech USA, Inc. | 1 | $15 |
| Phadia US Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,719
- DUPIXENT$102
How this compares
$7,536 in reported general payments places this provider in the 80th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 46 | $39,883 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $17,143 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $917 |
| Azithromycin | 28 | $565 |
| Ipratropium Bromide | 12 | $365 |
| Fluticasone Propionate | 21 | $246 |
| Prednisone | 29 | $88 |
| Pantoprazole Sodium | 15 | $54 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Green Bay
- Manar Al ShahrouriGreen Bay$61K
- Prince NtiamoahGreen Bay$37K
- Musab NusratGreen Bay$12K
- Jeremy RenzGreen Bay$10K
- Raul Mendoza AyalaGreen Bay$7K
- Ramya GorthiGreen Bay$6K
- Pamela SudGreen Bay$4K
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Hasnain BawaadamKenosha$686K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.